Last reviewed · How we verify
NCT06251076
Outpatient-based Teclistamab Step-up Dosing in Patients With Relapsed/Refractory Multiple Myeloma: Process Development in Academic and Community Centres, and Evaluating Impact on Caregiver Burden
Phase 4 trial testing Teclistamab in Multiple Myeloma in 15 participants. Currently enrolling.
15 June 2026
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 19 November 2024 |
| Primary completion | 15 June 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Teclistamab (TECLISTAMAB) — full drug profile →
- Tocilizumab (tocilizumab) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Relapsed Cancer — all drugs for Relapsed Cancer →
- Refractory Cancer — all drugs for Refractory Cancer →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Multiple Myeloma or Relapsed Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Median of day hospital encounters or hospitalizations as assessed by using descriptive statistics.
Time frame: 1 year
Used to guide development of written processes and protocols for teclistamab outpatient management. -
Median incidence of toxicities that are related to underlying disease, disease-related or background regimen as assessed by CTCAE v5.0.
Time frame: 1 year
Used to guide development of written processes and protocols for teclistamab outpatient management.
Sponsor's own description
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.
Lund T, Khandanpour C, Anguille S, Kisro J, et al · · 2025 · cited 2× · PMID 40571970 · DOI 10.1111/ejh.14444
Verify or expand the search:
- PubMed search for NCT06251076
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Teclistamab
Trials testing the same drug.
- NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07332507 — Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · Phase 1 · not yet recruiting
- NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat · Phase 2 · not yet recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06251076 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06251076.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing